Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Publish date:: February 22, 2019

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.

This Week's Must Reads

Mortality Rates Higher in Affiliate Hospitals,

Data From Routine Lung Cancer Visits Yield Research Insights,

Work to Begin on Part D Overhaul,

DTC Genetic Tests Deliver High False-Positive Rates ,

More Women Speaking at Medical Conferences ,

Must Reads in Hodgkin Lymphoma

Regimen shows promise as salvage for classical HL,

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.